Dear members, please see below MedTech Europe update, if your impacted please let me know at regulatory@bivda.org.uk
We would like to inform you about the latest chemical developments at ECHA and kindly ask you to indicate if any of the following impact your company by 11 March.
Please note that the substances highlighted in yellow are the ones previously identified as potentially in use by the sector.
CLP
- Consultations on harmonising classification and labelling. Feedback until 4 May – link here:
- methyl-1H-benzotriazole [1] and its inorganic salts, with the exception of those specified elsewhere in the Annex (EC 249-596-6 [1], CAS 29385-43-1 [1])
- 1H-benzotriazole [1] and its inorganic salts, with the exception of those specified elsewhere in the Annex (EC 202-394-1 [1], CAS 95-14-7 [1])
- tebufenpyrad (ISO); N-(4-tertbutylbenzyl)-4-chloro-3-ethyl-1-methyl-1H-pyrazole-5-carboxamide (EC -, CAS 119168-77-3)
In addition, ECHA launched two ad hoc consultations:
- 1-methylimidazole (EC 210-484-7, CAS 616-47-7) – have your say until 20 March 2026.
- glyphosate (ISO); N-(phosphonomethyl)glycine (EC 213-997-4, CAS 1071-83-6) – have your say until 31 March 2026.
- Proposal to harmonise classification and labelling – link here:
- acequinocyl (ISO); 3-dodecyl-1,4-dioxo-1,4-dihydronaphthalen-2-yl acetate (EC -, CAS 57960-19-7)
- Intentions to harmonise classification and labelling – link here:
- azoxystrobin (ISO); methyl (E)-2-{2-[6-(2-cyanophenoxy)pyrimidin-4-yloxy]phenyl}-3-methoxyacrylate (EC -, CAS 131860-33-8)
- α-cyano-3-phenoxybenzyl [1R-[1α(S*),3α]]-3-(2,2-dibromovinyl)-2,2-dimethylcyclopropanecarboxylate (EC 258-256-6, CAS 52918-63-5)
In addition, ECHA published the Assessment for Regulatory Needs Report for the following substance group::
